Arca
Skip to content
Tools
Tools

GRIN1, GRIN2B: Glutamate NMDA receptor; GRIN1/GRIN2B

Complex in Homo sapiens that 4 drugs act on.

  • Drugs that act on it: 4
  • Approved: 0
  • In phases 1 to 3: 4
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on GRIN1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved0

    Phase 30

      Phase 24

      • Radiprodil
      • EVT-101 free base
      • Rislenemdaz
      • Traxoprodil

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        • Avalo Therapeutics, Inc.125%
        • GRIN Therapeutics, Inc.125%

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Glutamate NMDA receptor; GRIN1/GRIN2B antagonist.
        RadiprodilPhase 2GRIN Therapeutics, Inc.Small moleculeAntagonist6
        EVT-101 free basePhase 2Johnson & JohnsonSmall moleculeAntagonist0
        RislenemdazPhase 2Avalo Therapeutics, Inc.Small moleculeAntagonist0
        TraxoprodilPhase 2PfizerSmall moleculeAntagonist0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.
        A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function VariantsRadiprodilPhase 1Not yet recruitingGRIN Therapeutics, Inc.Nov 17, 2026
        A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult ParticipantsRadiprodilPhase 1Active, not recruitingGRIN Therapeutics, Inc.Oct 21, 2026
        Radiprodil in Participants With Hepatic ImpairmentRadiprodilPhase 1RecruitingGRIN Therapeutics, Inc.Mar 9, 2026
        Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental DisorderRadiprodilPhase 3RecruitingGRIN Therapeutics, Inc.Nov 4, 2025
        Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type IIRadiprodilPhase 1 / Phase 2Active, not recruitingGRIN Therapeutics, Inc.Apr 30, 2024
        Honeycomb: Evaluation of Radiprodil in Children with GRIN-related DisorderRadiprodilPhase 1Active, not recruitingGRIN Therapeutics, Inc.Apr 19, 2023

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1907603, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.